Blueprint Medicines Profile

USD 0.18  0.22%
65.8Last Month High 88.32 
78.5Trading Day  High 83.94 

Exercise or conversion by Marion Dorsch of 9166 shares of Blueprint Medicines subject to Rule 16b-3

Blueprint Medicines Corporation insider trading alert for exercise of stock option (right to buy) by Marion Dorsch, Chief Scientific Officer, on November 24, 2017. This event was filed by Blueprint Medicines Corp with SEC on 2017-11-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Blueprint Medicines Summary

Blueprint Medicines Corporation (BPMC) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 99 people. Blueprint Medicines is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 3.21 B. Blueprint Medicines Corporation conducts business under Healthcare sector and is part of Biotechnology industry. This company has 39.2 M outstanding shares of which 2.17 M shares are currently shorted by private and institutional investors with about 5.59 trading days to cover. N/A currently holds about 390.65 M in cash with (103.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.97.
Check Blueprint Medicines Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.9 M408.7 M
Wellington Management Group LlpCommon Shares3.2 M223.4 M
View Blueprint Medicines Diagnostics

Selected Blueprint Medicines Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Blueprint Medicines Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
< 23% 
Blueprint Medicines Corporationration, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameBlueprint Medicines Corporation
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business Address38 Sidney Street, Suite 200, Cambridge, MA 02139, United States
CIK Number01597264.0
Contact Number617 374 7580
CurrencyUSD - US Dollar


Blueprint Medicines Analyst Recommendations
Target PriceAdvice# of Analysts
Blueprint Medicines Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Blueprint Medicines Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Blueprint Medicines Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.71March 10, 2017
Blueprint Medicines Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate